Sequel Med Tech, Senseonics to Integrate Eversense 365 CGM into twiist AID System

Sequel Med Tech and Senseonics began a commercial development agreement to integrate Sequel’s twiist automated insulin delivery (AID) system powered by Tidepool with Senseonics’ Eversense 365 continuous glucose monitor (CGM).

Thanks to this collaboration, twiist will become the first AID system compatible with Eversense 365, which is the first one-year CGM system. The duo hopes to offer type 1 diabetes patients more flexibility and personalization in managing their diabetes.

The agreement provides type 1 diabetes patients the option of a one-year CGM that integrates with the twiist AID system. The integrated system aims to offer more tools to manage care, which can lead to better glucose control, more convenience, and more flexibility.

The twiist AID system, which obtained FDA clearance in March 2024, directly measures volume of insulin delivered with every micro-dose. It’s cleared for people six and up with type 1 diabetes. Its twiist Loop algorithm—powered by the diabetes community-driven Tidepool Loop—lets the system automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels.

Eversense 365 earned FDA clearance in September 2024 as an integrated continuous glucose monitoring (iCGM) system for people with diabetes. Senseonics and Sequel have begun integrating Eversense 365 with twiist. The expanded CGM compatibility hopes to provide more personalization, choice, and potential for better outcomes.

The integration is anticipated to become available in Q3 of this year.

“Sequel is committed to investing in innovations that empower people with diabetes with options in how they manage their diabetes,” said Sequel co-founder and CEO Alan Lotvin, MD. “By partnering with Senseonics, a company pioneering long-duration CGM, we aim to deliver the flexibility people want to personalize their diabetes management on their terms.”

“This collaboration with Sequel marks a significant step forward in transforming diabetes care,” said added Tim Goodnow, Ph.D., president and CEO of Senseonics. “People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management. The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies to simplify diabetes management, providing users with an AID solution that unlocks the full experience of our year-long CGM technology.”